223 related articles for article (PubMed ID: 22218302)
1. Antitumor effects of bladder cancer-specific adenovirus carrying E1A-androgen receptor in bladder cancer.
Zhai Z; Wang Z; Fu S; Lu J; Wang F; Li R; Zhang H; Li S; Hou Z; Wang H; Rodriguez R
Gene Ther; 2012 Nov; 19(11):1065-74. PubMed ID: 22218302
[TBL] [Abstract][Full Text] [Related]
2. Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.
Wang L; Zhang Y; Zhao J; Xiao E; Lu J; Fu S; Wang Z
Tumour Biol; 2014 Nov; 35(11):10879-90. PubMed ID: 25085582
[TBL] [Abstract][Full Text] [Related]
3. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
4. Construction of urothelium-specific recombinant adenovirus and its inhibition in bladder cancer cell.
He XD; Wang ZP; Wei HY; Zhou Q; Wang DG; Tian JQ; Fu SJ; Rodriguez R
Urol Int; 2009; 82(2):209-13. PubMed ID: 19322012
[TBL] [Abstract][Full Text] [Related]
5. Prostate stem cell antigen enhancer and uroplakin II promoter based bladder cancer targeted tissue-specific vector.
Wang D; Wang Z; Tian J; He X; Chowdhury WH; Zhang X; Li S; Rodriguez R
Urol Oncol; 2010; 28(2):164-9. PubMed ID: 18440837
[TBL] [Abstract][Full Text] [Related]
6. A novel bladder cancer - specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression.
Cao W; Tian J; Li C; Gao Y; Liu X; Lu J; Wang Y; Wang Z; Svatek RS; Rodriguez R
Virol J; 2017 Aug; 14(1):149. PubMed ID: 28789701
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined treatment of radiation and tissue-specific recombinant oncolytic adenovirus on bladder cancer cells.
Zhang H; Wang F; Mao C; Zhang Z; Fu S; Lu J; Zhai Z; Li R; Li S; Rodriguez R; Wang Z
Int J Radiat Biol; 2017 Feb; 93(2):174-183. PubMed ID: 27600610
[TBL] [Abstract][Full Text] [Related]
8. Teratogenic Toxicity Evaluation of Bladder Cancer-Specific Oncolytic Adenovirus on Mice.
Lu K; Wang F; Ma B; Cao W; Guo Q; Wang H; Rodriguez R; Wang Z
Curr Gene Ther; 2021; 21(2):160-166. PubMed ID: 33334289
[TBL] [Abstract][Full Text] [Related]
9. Lentivirus-mediated p21/Waf-1 short hairpin RNA enhances the cytotoxic effects and replicative potential of a bladder cancer-specific oncolytic adenovirus in vitro.
Shi J; Fu S; Wang L; Tao Y; Rodriguez R; Wang Z
Anticancer Drugs; 2017 Jan; 28(1):88-96. PubMed ID: 27622605
[TBL] [Abstract][Full Text] [Related]
10. Conditionally replicating adenovirus-mediated gene therapy in bladder cancer: an orthotopic in vivo model.
Melquist JJ; Kacka M; Li Y; Malaeb BS; Elmore J; Baseman AG; Hsieh JT; Koeneman KS
Urol Oncol; 2006; 24(4):362-71. PubMed ID: 16818192
[TBL] [Abstract][Full Text] [Related]
11. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
12. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
13. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.
Zhang J; Lai W; Li Q; Yu Y; Jin J; Guo W; Zhou X; Liu X; Wang Y
Biochem Biophys Res Commun; 2017 Sep; 491(2):469-477. PubMed ID: 28698142
[TBL] [Abstract][Full Text] [Related]
14. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
15. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
[TBL] [Abstract][Full Text] [Related]
16. [Gene therapy study on bladder cancer with recombinant adenoviral vector carrying LRIG1 gene driven by Survivin promoter].
Yan ZJ; Cheng Y; Jiang JH; Hu JS; Shi XD
Zhonghua Wai Ke Za Zhi; 2012 Aug; 50(8):732-6. PubMed ID: 23157908
[TBL] [Abstract][Full Text] [Related]
17. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC
Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284
[TBL] [Abstract][Full Text] [Related]
18. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
19. Conditionally replicating adenovirus therapy utilizing bone sialoprotein promoter (Ad-BSP-E1a) in an in vivo study of treating androgen-independent intraosseous prostate cancer.
Li Y; Kacka M; Thompson M; Hsieh JT; Koeneman KS
Urol Oncol; 2011; 29(6):624-33. PubMed ID: 19963408
[TBL] [Abstract][Full Text] [Related]
20. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
